RxDoctor Payments Data

Scott Kolbaba, MD

Internal Medicine · Wheaton, ILNPI 1396776613

Payments from drug & device makers

$10,611in general payments, 2019–2025

Across 636 payments — averaging $16.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$1K
  • Kowa Pharmaceuticals America, Inc.$963
  • AstraZeneca$791
  • Amgen$783
  • Lilly USA, LLC$672
  • plus $5K from 41 others

What the payments were for

  • Speaking & faculty fees$150%
  • Food & beverage$10,48199%
  • Education$1151%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$10,611 in reported general payments places this provider in the 95th percentile of 5,182 internal medicine providers in Illinois.

See all internal medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$297,069
Medicare patients
334
Services billed
4,584

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban84$80,866
OzempicSemaglutide43$41,670
MounjaroTirzepatide30$34,772
XareltoRivaroxaban42$34,560
MyrbetriqMirabegron55$26,545
RybelsusSemaglutide15$22,689
JardianceEmpagliflozin21$20,919
Repatha SureclickEvolocumab16$14,306
JanuviaSitagliptin Phosphate12$13,318
Repatha SyringeEvolocumab12$10,804
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$10,692
LinzessLinaclotide17$9,522
Rivastigmine19$4,494
Levothyroxine Sodium275$4,145
Rosuvastatin Calcium263$3,520

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$450$80,86684 claims
Novo NordiskOzempic, Rybelsus$1,035$64,35958 claims
Lilly USA, LLCMounjaro$672$34,77230 claims
Johnson & JohnsonXarelto$658$34,56042 claims
Astellas Pharma US IncMyrbetriq$218$26,54555 claims
Boehringer IngelheimJardiance$650$20,91921 claims
MerckJanuvia$55$13,31812 claims
GSKTrelegy Ellipta, Arnuity Ellipta$475$13,31631 claims
AbbVieLinzess, Synthroid$1,097$12,93956 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,182 internal medicine providers in Illinois.

Other internal medicine in Wheaton

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →